PharVision Advisers’s Ellington Financial EFC Stock Holding History

PharVision Advisers’s Portfolio EFC Stock Details EFC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,267	Closed	-$169K	–	80
2026 Q1	$169K	Buy	+14,267	New	+$181K	1.72%	6

Other funds holding EFC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $83.9B AUM 60.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DFG

Delphi Financial Group Wilmington, Delaware $202M AUM 21.25% 1-Year Est. Return

PharVision Advisers's EFC Position: Q2 2026 in Review

PharVision Advisers sold out of Ellington Financial (EFC) in Q2 2026, closing a stake of 14,267 shares — an estimated $169K sold.

PharVision Advisers first reported a position in EFC in Q1 2026 and held it in 1 quarter. The position peaked at $169K in Q1 2026. 248 funds tracked by Wall St. Rank hold EFC as of Q2 2026.

PharVision Advisers reported no remaining Ellington Financial position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 14,267 Ellington Financial shares in Q2 2026, an estimated $169K.
PharVision Advisers first reported a position in Ellington Financial in Q1 2026 and held it in 1 quarter.
PharVision Advisers's Ellington Financial position peaked at $169K in Q1 2026.
248 funds tracked by Wall St. Rank held Ellington Financial as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.